FDA Adverse Event Reporting System

FDA Adverse Event Reporting System
Name	FDA Adverse Event Reporting System
Acronym	FAERS
Owner	Food and Drug Administration
Country	United States
Established	1993

FDA Adverse Event Reporting System

The FDA Adverse Event Reporting System is a pharmacovigilance database maintained by the Food and Drug Administration to collect post-marketing reports of adverse events and medication errors for products regulated by the Food and Drug Administration. It supports post-approval safety surveillance for pharmaceuticals, biologics, and therapeutic devices, informing regulatory decisions by linking spontaneous reports to signal detection, risk assessment, and labeling actions. FAERS interfaces with other surveillance systems and stakeholders including Centers for Disease Control and Prevention, National Institutes of Health, and international counterparts such as the European Medicines Agency and World Health Organization.

Overview

FAERS aggregates individual case safety reports submitted by healthcare professionals, consumers, and manufacturers to monitor adverse events associated with drugs, biologics, and therapeutic devices. It functions alongside systems like the Vaccine Adverse Event Reporting System, enabling data mining and disproportionality analyses to detect safety signals that may warrant further evaluation by entities such as the Advisory Committee on Immunization Practices or the Advisory Committee for Pharmaceutical Science. FAERS contributes evidence used in regulatory actions by the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.

History and Development

FAERS originated from legacy systems developed during the 20th century to capture post-marketing safety issues after landmark events like the Thalidomide tragedy and legislation including the Food, Drug, and Cosmetic Act. Modernization accelerated in the 1990s under initiatives related to the Prescription Drug User Fee Act and information technology upgrades influenced by standards from organizations such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and the World Health Organization's Uppsala Monitoring Centre. Key milestones involved harmonizing terminologies with Medical Dictionary for Regulatory Activities and adopting electronic submission standards aligned with Health Level Seven International and Electronic Common Technical Document frameworks.

Reporting Mechanisms and Data Sources

Reports enter FAERS via mandatory manufacturer submissions, voluntary reports from clinicians and patients, and interagency exchanges with partners like the Centers for Medicare & Medicaid Services and the Department of Veterans Affairs. Manufacturers submit Individual Case Safety Reports according to regulations implementing statutes such as the Federal Food, Drug, and Cosmetic Act and FDA guidance documents. Data elements derive from sources including clinical trial follow-up, spontaneous adverse event reports sent to national pharmacovigilance centers like the Uppsala Monitoring Centre, and case reports published in journals such as The New England Journal of Medicine or The Lancet that may prompt voluntary reporting by investigators.

Data Structure, Access, and Analysis

FAERS data are structured into relational tables capturing report identification, patient demographics, drug exposure, reaction terms, outcomes, and narrative elements mapped to controlled vocabularies like Medical Dictionary for Regulatory Activities and standardized coding from the National Drug Code directory. Public datasets are released periodically in electronic formats for researchers, epidemiologists, and analysts from institutions such as Johns Hopkins University, Harvard University, and Mayo Clinic to conduct disproportionality analyses, temporal trend assessments, and case series. Analytical approaches include proportional reporting ratios, Bayesian data mining methods exemplified by the Empirical Bayes Geometric Mean and tools used by data scientists affiliated with groups like Centers for Disease Control and Prevention and European Centre for Disease Prevention and Control.

Use in Pharmacovigilance and Public Health

Regulatory bodies including the Food and Drug Administration, European Medicines Agency, and Health Canada use FAERS-derived signals to prioritize investigations, update safety communications, and modify product labeling or implement risk evaluation and mitigation strategies. Public health stakeholders such as the Centers for Disease Control and Prevention and National Institutes of Health may integrate FAERS findings with epidemiologic studies, registry data from the National Cancer Institute, and surveillance datasets from the Behavioral Risk Factor Surveillance System to assess population-level risks and benefit–risk profiles for interventions like vaccination programs and chronic disease therapies.

Limitations and Criticisms

FAERS is subject to limitations raised by academic centers like Johns Hopkins University, policy organizations such as the Brookings Institution, and investigative reporting in outlets like The New York Times and The Washington Post. Constraints include underreporting, reporting bias, duplicate records, variable data quality, incomplete denominator information, and inability to establish causality without complementary epidemiologic studies from institutions like Centers for Disease Control and Prevention or randomized evidence from trials published in The Lancet. Critics point to challenges in signal validation, transparency concerns discussed in hearings before bodies such as the United States Congress, and legal disputes involving manufacturers and plaintiffs represented in courts including the United States Court of Appeals.

Regulatory and Legal Context

FAERS operates under statutory authorities and regulatory frameworks governed by the Food, Drug, and Cosmetic Act and FDA rulemaking implementing post-marketing safety reporting requirements. Compliance obligations for manufacturers are enforced through agency guidances, administrative actions, and interactions with other agencies such as the Department of Health and Human Services and oversight by committees including the Advisory Committee for Pharmaceutical Science. Legal context includes litigation referencing FAERS data in matters adjudicated in the United States District Court system and policy debates in venues such as the United States Senate and House of Representatives regarding surveillance funding, transparency, and data-sharing arrangements with global regulators like the European Medicines Agency and the World Health Organization.

Category:Pharmacovigilance